New daily persistent headache: A diagnosis, a syndrome, or a clinical placeholder?

Notice: Blog posts are not subject to review by MedLink Neurology’s Editorial Board. MedLink acknowledges using artificial intelligence to assist in the creation of blog posts.

Among primary headache disorders, few diagnoses generate as much uncertainty and debate as new daily persistent headache. Patients with this condition often describe the abrupt onset of an unremitting headache that becomes continuous within 24 hours and then persists for months or years without meaningful remission.

For some clinicians, new daily persistent headache represents a distinct biologic headache syndrome with characteristic clinical features. For others, it functions more as a descriptive label encompassing multiple poorly understood disorders that share only a common pattern of onset and persistence.

The controversy surrounding new daily persistent headache reflects broader challenges in headache medicine: how to classify syndromes that lack clear biomarkers, overlap extensively with other headache phenotypes, and may arise from heterogeneous mechanisms.

An unusual clinical presentation

One reason new daily persistent headache attracted historical attention is that patients can often identify the exact day, or even hour, the headache began.

This contrasts with migraine and tension-type headache, which more commonly evolve gradually over time.

Patients frequently describe:

• Abrupt onset during ordinary daily activity
• Persistent headache from onset onward
• Lack of meaningful headache-free periods
• Resistance to standard therapies

Some report onset after:

• Viral illnesses
• Influenza-like syndromes
• Surgery
• Stressful life events
• Minor head trauma

Others describe no identifiable trigger at all.

The dramatic onset pattern contributed to the idea that new daily persistent headache might represent a distinct disorder rather than simply chronic migraine developing rapidly.

A controversial diagnostic category

New daily persistent headache was formally incorporated into headache classification systems relatively recently compared with more established primary headache disorders. Yet disagreement quickly emerged regarding what the diagnosis actually represents. Several controversies persist:

• Is new daily persistent headache a single disorder or multiple disorders grouped together?
• Does it overlap substantially with chronic migraine?
• Are postinfectious cases biologically distinct?
• Should refractory secondary headaches be excluded more aggressively?
• Does the diagnosis risk becoming a “wastebasket” category for unexplained chronic headache?

The syndrome’s heterogeneity complicates the interpretation of research. Some patients exhibit migrainous features such as photophobia and nausea, whereas others resemble chronic tension-type headache. Some improve spontaneously, whereas others remain severely disabled for decades.

This variability has led some investigators to question whether new daily persistent headache has sufficient biologic coherence to function as a single diagnostic entity.

The postinfectious hypothesis

One recurring theory proposes that at least some cases represent a postinfectious neuroinflammatory syndrome. Interest in this hypothesis increased because many patients report headache onset following viral illness.

Earlier studies suggested possible associations with Epstein-Barr virus and other infections, although findings have remained inconsistent. The coronavirus disease 2019 pandemic renewed interest in this possibility. Persistent daily headache emerged as one of many reported postviral symptoms in some patients following severe acute respiratory syndrome coronavirus 2 infection.

However, establishing causation remains difficult. Viral illnesses are common, and chronic headache disorders frequently emerge during periods of physiologic or psychological stress. Nevertheless, the postinfectious model continues to attract attention because it may partially explain the abrupt onset and treatment resistance observed in some patients.

Diagnostic uncertainty and patient frustration

The controversy surrounding new daily persistent headache has important practical consequences for patients.

Many individuals undergo years of evaluation with repeated neuroimaging, lumbar punctures, medication trials, dietary modifications, alternative therapies, and specialist consultations. Despite extensive investigation, patients are often told that testing is normal while symptoms remain severe and disabling.

Some patients report feeling marginalized because the diagnosis lacks the recognition and research infrastructure associated with migraine or cluster headache. Others encounter skepticism from clinicians unfamiliar with the disorder.

At the same time, neurologists face legitimate challenges in distinguishing primary new daily persistent headache from secondary causes of persistent headache, including:

• Spontaneous intracranial hypotension
• Idiopathic intracranial hypertension
• Chronic meningitis
• Cerebral venous sinus thrombosis
• Cervicogenic disorders
• Medication overuse headache

This overlap contributes further to diagnostic uncertainty.

What the controversy reveals about headache medicine

The debate surrounding new daily persistent headache reflects a broader reality in neurology: classification systems are often provisional frameworks rather than definitive biologic truths.

Many neurologic syndromes were initially grouped clinically before underlying mechanisms became clearer. Parkinson disease, epilepsy, and dementia syndromes all later proved biologically heterogeneous despite appearing clinically unified.

New daily persistent headache may ultimately follow a similar trajectory. What is currently labeled as a single disorder could eventually separate into multiple biologically distinct conditions with different mechanisms and treatment responses.

For now, the diagnosis occupies an uneasy position between a clearly defined disease entity and a descriptive clinical construct.

Yet regardless of classification debates, the suffering experienced by patients with persistent daily headache is real, often profound, and frequently underrecognized. The continuing controversy therefore reflects not merely academic disagreement, but the larger challenge of understanding chronic pain disorders that remain resistant to straightforward categorization.

References

Li D, Rozen TD. The clinical characteristics of new daily persistent headache. Cephalalgia. 2002;22(1):66-69. PMID 11993616

Prakash S, Shah ND. Post-infectious new daily persistent headache may respond to intravenous methylprednisolone. J Headache Pain 2010;11(1):59-66. PMID 19936615

Rozen TD. New daily persistent headache: clinical perspective. Headache 2011;51(4):641-9. PMID 21457251

Are you interested in contributing a post or becoming a guest blogger for MedLink? Contact us at editorial@medlink.com.